tbuckley/cabot-search huggingface dataset:
114P: Feasibility of electronic patient-reported outcomes (ePRO) assessment using a mobile app to monitor patients with advanced ALK+ NSCLC (ePROtector study)
Authors: D.H. Enrico, P.P. Levit, J.E. Gomez, F.D. Waisberg, A. Frydman, A.R. Rodriguez, F. Tsou, M.D. Peralta Tanco, C.S. Pupareli, A.L. Mendana, G. Canceco, C. Lopez Brugiavini, M. Revelli Ling, O. Ainur, M.R. Chacon, C.M. Martín
Journal: Journal of Thoracic Oncology (2025)
123TiP: TROPION-Lung14: A phase III study of osimertinib ± datopotamab deruxtecan (Dato-DXd) as first-line (1L) treatment for patients with EGFR-mutated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC)
Authors: S.B. Goldberg, M. Provencio Pulla, A.E. Lisberg, E. Mascarenhas, J. Tanizaki, Y. Cheng, H.R. Kim, Y. Liu, S. Feng, L. Zhang, L.D. Toms, J.C-H. Yang, S. Lu
Journal: Journal of Thoracic Oncology (2025)
124TiP: TROPION-Lung15: A phase III study of datopotamab deruxtecan (Dato-DXd) ± osimertinib vs platinum doublet chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) and disease progression on prior osimertinib
Authors: E. Nadal, P.K. Cheema, Y-L. Wu, M-J. Ahn, J. Tanizaki, S. Gharagoozloo, E. Nizialek, X. Shi, T. van der Gronde, H.A. Yu, D.S.W. Tan
Journal: Journal of Thoracic Oncology (2025)
99P: The effect of KRAS mutation subtypes on the efficacy of first-line pembrolizumab in stage IV non-small cell lung cancer patients with high PD-L1 expression
Authors: Patrizia Froesch, L. Motta, S. Epistolio, L. Grassi Bertazzi, F. Molinari, M. Imbimbo, A. Valera, J. Pankovics, B. Pedrazzini, S. Freguia, L. Giudici, M. Frattini
Journal: Journal of Thoracic Oncology (2025)
117P: Natural language processing (NLP)-driven analysis of metastatic non-small cell lung cancer (mNSCLC) outcomes: A real-world (RW) study within Israel’s universal healthcare
Authors: R. Barak, M. Brezis, S. Viswanathan, M. Wang, I.I. Dhillon, S. Shamai, O. Merimsky, I. Wolf
Journal: Journal of Thoracic Oncology (2025)
125TiP: Phase I study of patritumab deruxtecan (HER3-DXd) in patients (pts) with advanced KRAS G12C non-small cell lung cancer (NSCLC): Study U102 cohort 5
Authors: L. Paz-Ares, C. Steuer, G. Ruiter, M. Nishio, H. Murakami, D-W. Kim, E. Felip, C.S. Baik, C-C. Lin, E. Massarelli, M-J. Ahn, X. Su, M. Fujimura, L. Pasupuleti, A. Aguilo, S. Esker, H.A. Yu, H. Hayashi, P.A. Jänne
Journal: Journal of Thoracic Oncology (2025)
104P: MOMENT disease registry: Patient characteristics and treatment patterns from interim enrollment analysis of patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring METexon 14 (METex14) skipping treated with systemic therapy
Authors: Michael Thomas, P. Christopoulos, M. Hochmair, I. Demedts, P. Wheatley-Price, G. Liu, J. Fuentes Pradera, N. Girard, S. Popat, N. Peled, G. Minuti, G. Lo Russo, E. Smit, A.L. Machado, D. Carbone, S.H. Mahmoudpour, P. Eggleton, A. Johne, E. Boutmy, D. Oksen
Journal: Journal of Thoracic Oncology (2025)
110P: Prediction of the individual risk for the development of brain metastases in patients with stage IV NSCLC without actionable genomic alterations: Data from the German CRISP registry (AIO-TRK-0315)
Authors: F. Acker, K. Wenger, M. Reck, C. Waller, P. Hoffknecht, A. Bethge, M. Jaenicke, A. Fleitz, C. Lennartz, P. Ludwig, A. Groth, A. Nusch, M. Reiser, M. Ludwig, M. Bendel, F. Griesinger, M. Thomas, W.E.E. Eberhardt, M. Sebastian
Journal: Journal of Thoracic Oncology (2025)
127TiP: RELATIVITY-1093: A randomized, phase III study of first-line nivolumab (NIVO) + relatlimab (RELA) high dose (HD) with platinum-doublet chemotherapy (PDCT) vs pembrolizumab (PEMBRO) + PDCT in patients with metastatic NSCLC having tumor PD-L1 expression ≥ 1% and non-squamous (NSQ) histology
Authors: S. Peters, N. Girard, H. Hayashi, N. Reinmuth, K.J. O’Byrne, F. Cappuzzo, E.B. Garon, Y-L. Wu, S. Lu, A. Qureshi, D. Kessler, S. Rabindran, P. Ravindran, M. Altan
Journal: Journal of Thoracic Oncology (2025)
108P: The information-seeking behaviour of health care providers for drug-drug interaction signals with lung cancer agents
Authors: D. Burger, L. Nijboer, M. van den Heuvel, S. Croes, D. van den Hurk, B. Piet, E. van De Garde, L. Hendriks, A.J. van der Wekken, R. Ter Heine
Journal: Journal of Thoracic Oncology (2025)
103P: Enhancing survival prediction in advanced non-small cell lung cancer (aNSCLC): A comparison of artificial intelligence (AI) derived prognostication and RECIST assessments in MYSTIC phase III trial
Authors: O.F. Khan, J. Riskas, S.A. Haider, O. Samorodova, J. Hennessy, V. Sivan, F. Baldauf-Lenschen, K.A. Patwardhan, Q. Li, H. Ravi Prakash
Journal: Journal of Thoracic Oncology (2025)
106P: AI-driven disease and care modelling and simulation: A framework for simulating real-world scenarios in non-small cell lung cancer (NSCLC)
Authors: A. Movschin, L. Bosquet, D. Perol, M. Rollot, L. Dry, C. Clemente, F. Al Nakib, M. Berthelot, M. Törnqvist
Journal: Journal of Thoracic Oncology (2025)
118P: Assessing informative censoring in trials testing immunecheckpoint inhibitors in NSCLC: A systematic review and a meta-research study
Authors: F. Vitale, S. D’Ambrosio, A. Avanzo, F. Salomone, A. Viggiano, L. Liguori, L. Longo, A. Russo, M.C. Isernia, F. Napolitano, A. Santaniello, L. Formisano, R. Bianco, A. Servetto
Journal: Journal of Thoracic Oncology (2025)
122TiP: TROPION-Lung10: Phase III study of datopotamab deruxtecan (Dato-DXd) + rilvegostomig in non-squamous (NSQ) advanced/metastatic (a/m) non-small cell lung cancer (NSCLC) with high PD-L1 expression and without actionable genomic alterations (AGAs)
Authors: T. Newsom-Davis, B. Solomon, B. Melosky, R. Heist, S. Lu, G. Pasello, J. Niewczas, M. Stachowiak, P. Lyfar, X. Shi, S.S. Ramalingam
Journal: Journal of Thoracic Oncology (2025)
109P: Enhancing enrollment to 1L NSCLC trials by allowing 1 prior cycle of standard of care (SOC): SUNRAY-01 experience
Authors: M.J. Hochmair, K.C. Arbour, M.V. Negrao, F. Cappuzzo, A-M.C. Dingemans, N. Girard, B.H. Gronberg, T.A. Leal, C. Lindsay, S. Lu, M. Nishio, L. Paz-Ares, M. Reck, J. Sabari, A. Spira, W. Nassib William Junior, A. Merced, K. Sheffield, C.M. Visseren-Grul, S. Peters
Journal: Journal of Thoracic Oncology (2025)
129TiP: A single arm phase II study evaluating intracranial efficacy of sacituzumab govitecan (SG) with bevacizumab (BEV) in patients (pts) with active, asymptomatic brain metastases (BM) from non-small cell lung cancer (NSCLC)
Authors: L. Hendriks, F. Bensch, W. Theelen, M. Anten, M. Broen, L. Jacobi-Postma, J. Appeldoorn, B. van den Bosch, S. Croes, R. van Geel
Journal: Journal of Thoracic Oncology (2025)
130TiP: High-dose aumolertinib as first-line treatment in advanced NSCLC patients harboring EGFR 21L858R mutation (AHEAD)
Authors: L.P. Lin, C.J. Deng, H.J. Bao, X. Luo, H. Su, J.Z. Hu, X.L. Cao
Journal: Journal of Thoracic Oncology (2025)
131TiP: TACTI-004: A double-blinded, randomized phase III trial in patients with advanced/metastatic non-small cell lung cancer receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (P) and chemotherapy (C) versus placebo + P + C
Authors: M. Majem, K.J. O’Byrne, G. Lo Russo, C. Mueller, F. Triebel
Journal: Journal of Thoracic Oncology (2025)
128TiP: ABBIL1TY NSCLC-06: A global, randomized, open-label, phase III trial of acasunlimab in combination with pembrolizumab (Pembro) vs docetaxel in checkpoint inhibitor (CPI)-experienced patients with PD-L1+ metastatic non-small cell lung cancer (mNSCLC)
Authors: L. Paz-Ares, B. Besse, M. Thomas, J.G. Aerts, J.C-H. Yang, J. Michalski, J. D’Olimpio, K. Kasahara, Y. Fujisaka, K. Rai, H.R. Kim, K.U. Park, M-J. Ahn, A. Georgiou, T. Mark, M. Sacchi, C. Aggarwal
Journal: Journal of Thoracic Oncology (2025)
126TiP: An open-label, single-arm, phase Ib exploratory study to evaluate the safety and efficacy of golidocitinib in combination with anti-PD-1 in locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with anti-PD-1 containing regimens
Authors: H. Zhong, X. Zhang
Journal: Journal of Thoracic Oncology (2025)
119P: Real-world first-line (1L) treatment characteristics and physician-reported areas of improvement for patients with advanced non-small cell lung cancer (aNSCLC) with PD-L1 expression ≥50% and without actionable genomic alternations (AGA) in Europe (EU), United States (US) and Asia
Authors: M. Sebastian, D.H. Owen, H. Kenmotsu, S. Viswanathan, S.K. Mhatre, C. Hogea, I.I. Dhillon, R. Gupta, C. Forshaw, H. Bailey, D. Rodriguez Abreu
Journal: Journal of Thoracic Oncology (2025)
116P: Predicting overall survival (OS) differences and treatment duration from longitudinal ai-driven imaging-based prognostication (IPRO) and first-line (1L) treatment status among patients with advanced non-small cell lung cancer (aNSCLC)
Authors: O.F. Khan, M. Alvi, M. Salluzzi, R. Bridges, J. Riskas, S.A. Haider, V. Sivan, O. Samorodova, J. Hennessy, D. Shah, F. Baldauf-Lenschen
Journal: Journal of Thoracic Oncology (2025)
115P: Exploring hypofractionated thoracic radiotherapy in stage IV NSCLC: Insights from a real-world retrospective study
Authors: S. Mansoorian, J. Lehmann, L. Käsmann, R. Gaus, C. Richlitzki, H. Kravutske, F. Putz, N-S. Schmidt-Hegemann, N. Reinmuth, A. Tufman, J. Dinkel, G. Sheikh, C. Belka, C. Eze
Journal: Journal of Thoracic Oncology (2025)
102P: Molecular characteristics and spatially resolved proteomic immune clusters reveal responsiveness of large cell neuroendocrine carcinomas of the lung (LCNEC) towards the Checkmate-9LA treatment protocol
Authors: M. Mueller, E. Philipp, P. Buechele, A. Riecke, C. Neumann, A. Arndt, K. Steinestel, R. Heller, M. Grunert, H. Witte, A. Bauer
Journal: Journal of Thoracic Oncology (2025)
136MO: Predictors of multidisciplinary tumor board adherence in stage III non-small cell lung cancer patients from a large multicenter study
Authors: M. Joerger, K-L. Koster, S. Yohasenan, A.S. Pakmak, M.T. Mark, I. Metaxas, C. Lips, F. Hitz, P. Leskow, C. Ludwig, P-M. Putora, M. Glatzer, T. Schneider, C. Caviezel, T. Mader, M. Mousavi, M. Blum, M. Frueh
Journal: Journal of Thoracic Oncology (2025)
132TiP: Phase Ib open-label study of trastuzumab deruxtecan (T-DXd) + rilvegostomig ± carboplatin as first-line (1L) treatment (Tx) for metastatic HER2-overexpressing (HER2-OE) non-small cell lung cancer (NSCLC): DESTINY-Lung03 (DL-03) part 4
Authors: D. Planchard, J.C-H. Yang, E. Nakajima, E. Schreffler, Y-T. Chang, J.R. Brahmer
Journal: Journal of Thoracic Oncology (2025)
LBA3: Sites of relapse and subsequent therapy in the BR.31 phase III study of durvalumab vs placebo in resected stage IB-IIIA NSCLC
Authors: V. Westeel, G. Goss, G. Darling, K. Nakagawa, B. Massuti Sureda, F. Perrone, S-A. McLachlan, J.H. Kang, Y-L. Wu, A-M.C. Dingemans, R. Dziadziuszko, M. Okada, L. Greillier, C. Audigier-Valette, F. Morin, S. Sugawara, E. Nadal, M.R. Stockler, K. Ding, C. O’Callaghan
Journal: Journal of Thoracic Oncology (2025)
135MO: Grading system of spread through air spaces is an independent predictor of recurrence in stage I invasive non-mucinous adenocarcinoma
Authors: J. Lee, S. Cho, J-H. Chung, J.W. Son, E. Lee, B.C-H. Shih, W. Jung, J.H. Jeon, K. Kim, S. Jheon
Journal: Journal of Thoracic Oncology (2025)
134TiP: Evaluation of an additional cohort of patients with non-small cell lung cancer (NSCLC) in the phase I/II duravelo-1 study of zelenectide pevedotin (BT8009), a bicycle toxin conjugate
Authors: C. Baldini, L. Verlingue, A. Italiano, L. Carter, G.S. Falchook, V. Boni, A. Dowlati, B. Doger De Spéville, E. Fontana, J. Rodon, C. Vicier, R. Balaraman, M. Barve, L. Demars, G. Brown, C. Xu, J. Bader, M. McKean
Journal: Journal of Thoracic Oncology (2025)
133TiP: A randomized phase III study of ivonescimab versus pembrolizumab as first-line treatment of metastatic non-small cell lung cancer as first-line treatment of metastatic non-small cell lung cancer with high tumor PD-L1 expression: HARMONi-7
Authors: A. Passaro, N. Girard, D. Rodriguez Abreu, M. Gumus, Y-L. Wu, K. Syrigos, R. Ramlau, E. Santos, D. Berz, C. Gandhi, N. Vokes, B. Wang, J. Rotow, P. Paik, J. Weiss, J. Agulnik, X. Bai, P. McGovern, A. Calles Blanco
Journal: Journal of Thoracic Oncology (2025)
147P: Radiomics-based multivariate classifiers to decode tumor immune microenvironment heterogeneity in surgically resected NSCLC patients
Authors: P. Tamarozzi, G. Mazzaschi, M. Balbi, R. Mura, C. Marrocchio, L. Moron Dalla Tor, L. Leo, R. Rosati, F. Pecci, A. Dodi, S. D’Agnelli, L. Gnetti, G. Bocchialini, F. Quaini, L. Ampollini, N. Sverzellati, M. Tiseo
Journal: Journal of Thoracic Oncology (2025)
151P: Real-world adjuvant treatment patterns in Chinese patients with resected stages I to III EGFR-mutated NSCLC: A multicenter observational study (ADDRESS, CATO-2001)
Authors: W. Liang, S. Jiang, P. Chen, Y. Chai, W. Liu, L. Liu, P. Song, Z. Wang, S. Zhang, H. Xin, J. Tan, S. Xu, H. Zhang, Y. Han, W. Shen, Z. Peng, M. Geng, G. Yu, X. Zhang, J. He
Journal: Journal of Thoracic Oncology (2025)
150P: Pathologic complete response (pCR) and major pathologic response (MPR) as surrogate endpoints of survival in immunotherapy trials for early-stage NSCLC
Authors: M. Tagliamento, V. Delucchi, G. Rossi, E. Cella, L. Barcellini, A. Bragoni, E. Chiappe, M. Lambertini, L. Boni, R. Ferrara, M. Brandão, I. Schmitt-Opitz, A-M.C. Dingemans, B. Besse, S. Michiels, E. Blondeaux
Journal: Journal of Thoracic Oncology (2025)
138P: Outcomes by treatment (tx) cycles (cyc) with perioperative nivolumab (NIVO) in patients (pts) with resectable NSCLC from CheckMate 77 T study
Authors: D. Moro-Sibilot, T. Cascone, M. Awad, J. Spicer, F. Tanaka, J. He, S. Lu, Y. Gao, H. Ito, L.D.O. Koch, A. Janssens, A. Alexandru, S. Bohnet, C.M. Bestvina, S. Bhatia, C. Coronado Erdmann, S.I. Blum, S. Lucherini, L. Li, M. Provencio Pulla
Journal: Journal of Thoracic Oncology (2025)
137MO: Impact of cardiac substructure dose on cardiotoxicity and overall survival (OS) in early-stage non-small cell lung cancer (ES-NSCLC) patients receiving stereotactic ablative body radiotherapy (SABR): Data from the interim analysis of the LUNG HEART study
Authors: M. Cerrato, S. Badellino, G. Petruzzellis, A. Celislami, M. Levis, U. Ricardi
Journal: Journal of Thoracic Oncology (2025)
139P: Global qualitative assessment of factors affecting multidisciplinary team (MDT) care in early-stage NSCLC
Authors: S. Schmid, T.A. Leal, H. Bahig, T.D.A. Pinto, C. Finlayson, R. Rawlinson, D. Simmons, M.K. Shanahan, M. Mancy, Y. Qiao, T.R. Rasmussen
Journal: Journal of Thoracic Oncology (2025)
144P: Perioperative immunotherapy treatment in resectable non-small cell lung cancer with KRAS mutation: A real-world study (Peri-R-01)
Authors: H. Zhong, F. Yao, B. Han, B. Zhang, R. Zhong, J. Teng, W. Zhang, R. Qiao, Y. Zhang, M. Li, J. Xu, J. Qian, Y. Kuang, L. Cheng, S. Wang, F. Qian, Z. Ruiying
Journal: Journal of Thoracic Oncology (2025)
145P: Efficacy and safety of aumolertinib as adjuvant therapy in resectable stage I A NSCLC with high-risk factors and EGFRsensitizing mutations (APPOINT)
Authors: B. Han, W.V. Fang, C. Chen, W. Zhang, B. Zhang, F. Yao, J-X. Shi, D. Yue, Y. Qi, Z. Zhu, J-B. Xie
Journal: Journal of Thoracic Oncology (2025)
142P: Identification of the lymph node metastasis atlas and optimal lymph node dissection strategy in patients with resectable lung invasive mucinous adenocarcinoma: A real-world multicentre study
Authors: J. He, J. Li, G. Zhang, C. Zheng, J. Jia, S. Xu, W. Zhao, Y. Liu, M. Yue, Y. Liu, S. Zhang, Y. Shen, Y. Han, J. Li, H. Yan, L. Xue, Y. Gao, F. Tan, S. Gao, Q. Xue
Journal: Journal of Thoracic Oncology (2025)
140P: Neoadjuvant lazertinib therapy guided by EGFR mutation detection in BALF for resectable lung cancer: Prospective real-world phase II study
Authors: I.A. Kim, H.J. Kim, J.Y. Hur, W.S. Kim, S.A. Lee, J.J. Hwang, Y.W. Kim, K.Y. Lee
Journal: Journal of Thoracic Oncology (2025)
146P: Sex differences in patient-reported outcomes following pulmonary resection for lung cancer: A systematic review
Authors: R. Costa, C. Beushausen, P. Duarte Dambrosio, L. Cmelak, R.S. Decker, A. Moumen, N. Mamdouh, E. Ilhan Sezer, F.L. Cecere, L. Bertolaccini, C. Pompili
Journal: Journal of Thoracic Oncology (2025)
169P: THASSOS-INTL Türkiye subset: Unveiling treatment patterns and clinical outcomes in resectable early-stage NSCLC
Authors: A. Sezer, A. Isikdogan, S. Sezgin Goksu, T. Goksel, D. Erdem, O. Yazici, M. Kiyik, Y. Kilic
Journal: Journal of Thoracic Oncology (2025)
154P: Prognostic significance of T cell subtypes in the tumour microenvironment for recurrence following curative-intent resection in early-stage NSCLC
Authors: A. McGuire, S. Martin, J. Naso, K. Noureddine, R. Xiang, P. Arora, M.D. Guillaud, C. Ho, C. Macaulay
Journal: Journal of Thoracic Oncology (2025)
167P: Neoadjuvant (NEO) versus perioperoperative (PERIOP) chemo-immunotherapy (CT-ICI) according to pathological response (PR) in resectable non-small cell lung cancer (NSCLC): An individual patient data (IPD) analysis
Authors: A. Nuccio, F. Salomone, A. Servetto, B. Ricciuti, D. Marinelli, A. Bulotta, G. Veronesi, M.C. Garassino, V. Torri, B. Besse, G. Viscardi, R. Ferrara
Journal: Journal of Thoracic Oncology (2025)
160P: Comparison of outcomes between anatomical segmentectomy and stereotactic body radiation therapy in early-stage non-small cell lung cancer: A single-center retrospective analysis
Authors: R. Costa, C. van der Elzen, K. Kostopanagiotou, F. Sousa, J. Casalta Lopes, A. Leite Moreira, L. Osório
Journal: Journal of Thoracic Oncology (2025)
178TiP: Bronchoalveolar lavage (BAL) to accelerate time to molecular diagnosis in early-stage lung cancer (AToM-001)
Authors: B.E. Jimenez Munarriz, K. Czarnecka-Kujawa, M. Rabey, L. Le, A. Salvarrey, T. Zhang, T. Stockley, H. Feilotter, P. Sabatini, N. Leighl
Journal: Journal of Thoracic Oncology (2025)
179TiP: Lorlatinib as neoadjuvant treatment in stage IB-IIIB ALK-rearranged non-small cell lung cancer (NEOLORA)
Authors: F. Yang, X. Yan, H. Zhao, Q. Chu, J. Fan, H. Liu, Y. Xia, X. Yan, D. Yang, L. Zhou, G. Chang, K. Sun
Journal: Journal of Thoracic Oncology (2025)
LBA4: Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable (UR) stage III EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC): Updated overall survival (OS) analysis from the LAURA study
Authors: S.S. Ramalingam, M. Ozguroglu, M-J. Ahn, X. Dong, J.C-H. Yang, S. Oizumi, K. Goto, M.A. Cobo Dols, S-W. Kim, T-C. Hsia, J. Chindaprasirt, F. Fujiki, N.I. Valdiviezo Lama, I.A. Casarini, T. Kato, X. Huang, A.L. Evans, A.L. Bolanos, S. Lu
Journal: Journal of Thoracic Oncology (2025)
163P: Transportability of RATIONALE-315 trial outcomes to the European patient population in resectable non-small cell lung cancer
Authors: F. Passiglia, E. Priedane, S. Mardiguian, M. Farraia, A. Pandey, P. Shukla, C. von Wilamowitz-Moellendorff, S. Rivolo, A. Mendoza, S. Leaw, Y. Wang, X. Lin, V. Kapetanakis
Journal: Journal of Thoracic Oncology (2025)
174P: Health-related quality of life (HRQoL) assessment in trials testing tyrosine kinase inhibitors (TKI) or immune checkpoint inhibitors (ICIs) in resectable non-small cell lung cancer (NSCLC)
Authors: F. Salomone, G. Novero, A. Servetto, O. Ciani, M. Di Maio, G. Pravettoni, C. Pompili
Journal: Journal of Thoracic Oncology (2025)
175TiP: ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC
Authors: S. Schmid, G. Dimopoulou, P.E. van Schil, S.P. Finn, B. Solomon, S. Popat, M. Pérol, L. Landi, K. Oselin, C. Aigner, H. Roschitzki-Voser, E. Grolimund, B. Ruepp, U. Dafni, R.A. Stahel, S. Peters
Journal: Journal of Thoracic Oncology (2025)
170P: Real-world (RW) characteristics, treatment (Tx) patterns and biomarker use in patients (pts) with early stage non-small cell lung cancer (ES NSCLC) in Greece: Results of the retrospective INFINITY study
Authors: S. Agelaki, G. Mountzios, A. Koumarianou, I. Boukovinas, H. Linardou, G. Goumas, C. Christodoulou, V. Ramfidis, C. Emmanouilidis, P. Kosmidis, I. Korantzis, D. Bafaloukos, F. Zagouri, D. Mauri, M. Demiri, A. Desiniotis, I. Dimitriadis, E. Iliopoulou, K. Syrigos
Journal: Journal of Thoracic Oncology (2025)
172P: Qualitative study to identify drivers and barriers of adherence to adjuvant osimertinib for early-stage EGFR positive non-small cell lung cancer (NSCLC)
Authors: N. Florez, V. Cooper, Y. Liang, R.J-B. Salomonsen, M. Sandelin, L. Eliasson, A. Moore, J. Rotow
Journal: Journal of Thoracic Oncology (2025)
173P: Clinical and pathological insights into EGFR-mutated early-stage non-small cell lung cancer (NSCLC): Associations with survival, PD-L1 expression, and second primary neoplasms
Authors: B. Del Rio, H. Bote-De Cabo, M. Peressini Álvarez, C. Serrano Gomez, J. Torres Jimenez, M. Zurera Berjaga, S. Masini, O.C. García, D. Pelegrina, J.A. Nunez Sobrino, V. Adradas, S. Ponce Aix, L. Paz-Ares, J. Zugazagoitia, J. Baena Espinar
Journal: Journal of Thoracic Oncology (2025)
159P: Patient and clinician preferences for adjuvant treatment in early-stage non-small cell lung cancer (NSCLC)
Authors: C. Michaels-Igbokwe, H. Collacott, A. Doldos, M. Sandelin, J. Pye, L. Servidio, Y. Liang, R.J-B. Salomonsen
Journal: Journal of Thoracic Oncology (2025)
156P: Sublobar resections for stage I NSCLC: A real-world validation of clinical trials through an individual patient data meta-analysis
Authors: F.T. Gallina, D. Marinelli, P. Bertoglio, F. Guerrera, R. Tajè, M. Chiappetta, F. Lococo, F. Cappuzzo, G. Veronesi
Journal: Journal of Thoracic Oncology (2025)
161P: Comparative analysis of two cohorts of patients with NSCLC: Persistent disease vs complete response after neoadjuvant treatment with chemoimmunotherapy
Authors: M. Sereno, M. Morales, A. Collazo Lorduy, D. Gomez De Antonio, L. Gutierrez Sainz, J. Baena Espinar, L. Cabezon Gutierrez, R. López Castro, J. Rubio Perez, G. Fernandez-Hinojal, C. Aguado de la Rosa, P. Cruz Castellanos, L.E. Chara Velarde, E. Jimenez Aguilar, A. Lopez Martin, J. Rogado, B. Losada Vila, S. Falagán Martínez, G. Rubio, E. Bernal Hertfelder
Journal: Journal of Thoracic Oncology (2025)
211P: Five-year survival outcomes from PIT-2: S-1 plus cisplatin with concurrent radiotherapy followed by surgery in stage IIIA (N2) lung squamous cell carcinoma
Authors: K. Takamochi, M. Tsuboi, M. Okada, S. Niho, S. Ishikura, S. Oyamada, T. Yamaguchi, F. Tanaka, H. Suzuki, T. Koike, M. Endo, S. Shiono, N. Okumura, K. Suzuki
Journal: Journal of Thoracic Oncology (2025)
210P: Prognostic Value of minimal residual disease in the NADIM II trial
Authors: R. Serna-Blasco, E. Nadal, J.L. Gonzalez-Larriba, A. Martinez-Marti, R. Bernabe Caro, J. Bosch-Barrera, V. Calvo De Juan, M.A. Insa Molla, N. Reguart, J. de Castro Carpeño, C. Aguado de la Rosa, R. Palmero Sanchez, F. Hernando, J. Martín-López, M.E. Lazaro, J. Hayes, A. Cruz-Bermudez, B. Massuti Sureda, A. Romero, M. Provencio Pulla
Journal: Journal of Thoracic Oncology (2025)
205P: EGFR-TKI combined with chemotherapy versus EGFR-TKI alone for locally advanced EGFR-mutant NSCLC: A real-world study
Authors: Y. Jiang, Y. Lin, H. Deng, W. Fu, Y. Huang, H. Liang, J. He, W. Liang
Journal: Journal of Thoracic Oncology (2025)
206P: Radiotherapy-induced atrial fibrillation in lung cancer: Should pulmonary veins be considered as organs at risk?
Authors: M. Ben Rejeb, S. Abdessaied, G. Abdessatar, S. Ghorbel, R. Toumi, R. Oueslati, A. Hamdoun, L. Ghorbal, L. Kochbati
Journal: Journal of Thoracic Oncology (2025)
207P: Phase I study of reirradiation (ReRT) with NBTXR3 for inoperable locoregional recurrent non-small cell lung cancer (NSCLC)
Authors: S. Gandhi, E. Chang, A. Chen, S. Chun, S.H. Lin, R. Maguire, M.S. Ning, J. Bronk, D. Qian, J.Y. Chang, J.W. Welsh, Z. Liao, R. Sheth, R. Casal
Journal: Journal of Thoracic Oncology (2025)